Audentes Therapeutics (NASDAQ:BOLD) Posts Quarterly Earnings Results, Beats Expectations By $0.07 EPS
Audentes Therapeutics (NASDAQ:BOLD) released its earnings results on Thursday. The biotechnology company reported ($1.00) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.07) by $0.07, Briefing.com reports. During the same period last year, the company earned ($0.97) EPS.
BOLD stock traded up $1.49 during trading on Friday, hitting $28.57. The company had a trading volume of 614,500 shares, compared to its average volume of 490,503. Audentes Therapeutics has a 12 month low of $17.95 and a 12 month high of $41.65. The stock has a market cap of $1.24 billion, a price-to-earnings ratio of -8.40 and a beta of 1.77. The firm has a 50-day moving average price of $28.15 and a 200-day moving average price of $34.34.
In related news, CEO Matthew R. Patterson sold 20,000 shares of the company’s stock in a transaction dated Monday, August 12th. The shares were sold at an average price of $34.04, for a total value of $680,800.00. Following the transaction, the chief executive officer now owns 135,368 shares in the company, valued at approximately $4,607,926.72. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Also, Director Louis G. Lange sold 10,000 shares of the stock in a transaction that occurred on Monday, September 23rd. The stock was sold at an average price of $32.16, for a total transaction of $321,600.00. Following the transaction, the director now owns 276,044 shares in the company, valued at approximately $8,877,575.04. The disclosure for this sale can be found here. 5.30% of the stock is owned by insiders.
Audentes Therapeutics Company Profile
Audentes Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases caused by single gene defects. The company is developing AT132, which is in Phase I/II clinical studies for the treatment of X-linked myotubular myopathy (XLMTM); AT342 that is in Phase I/II clinical studies to treat crigler-najjar syndrome; AT845, which is in preclinical studies for the treatment of pompe disease; and AT307 to treat CASQ2 subtype of catecholaminergic polymorphic ventricular tachycardia.
Further Reading: Bid-Ask Spread
Receive News & Ratings for Audentes Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Audentes Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.